May 2024
1. JANUZZI JL JR, Liu Y, Sattar N, Yavin Y, et al
   Vascular endothelial growth factors and risk of cardio-renal events: Results from the CREDENCE trial.
   Am Heart J. 2024;271:38-47.
   

   >> Share

   
   April 2024
2. GAGNON LR, Hazra D, Perera K, Wang K, et al
   Uptake of SGLT2i and Outcomes in Patients with Diabetes and Heart Failure: A Population-Based Cohort and a Specialized Clinic Cohort.
   Am Heart J. 2024 Apr 24:S0002-8703(24)00094-2. doi: 10.1016/j.ahj.2024.
   

   >> Share

   
   
3. HEERSPINK HJ, Provenzano M, Vart P, Jongs N, et al
   Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria.
   Am Heart J. 2024;270:125-135.
   

   >> Share

   
   March 2024
4. ANAND SS, Aboyans V, Bosch J, Debus S, et al
   Identifying the highest risk vascular patients: Insights from the XATOA registry.
   Am Heart J. 2024;269:191-200.
   

   >> Share

   
   
5. HAMO CE, Schlamp F, Drenkova K, Jindal M, et al
   Burden of cardiometabolic risk factors and vascular health.
   Am Heart J. 2024;269:201-204.
   

   >> Share

   
   February 2024
6. RAO VN, Sharma A, Stebbins A, Buse JB, et al
   Regional variation in cause of death in patients with type 2 diabetes: insights from EXSCEL: Cause of Death in Type 2 Diabetes.
   Am Heart J. 2024 Feb 21:S0002-8703(24)00040-1. doi: 10.1016/j.ahj.2024.
   

   >> Share

   
   
7. ANDERSEN CF, Larsen JH, Jensen J, Omar M, et al
   Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial program.
   Am Heart J. 2024 Feb 14:S0002-8703(24)00032-2. doi: 10.1016/j.ahj.2024.
   

   >> Share

   
   November 2023
8. SALAHUDDIN T, Hebbe A, Daus M, Essien UR, et al
   Trends and Site-level Variation of Novel Cardiovascular Medication Utilization among Patients Admitted for Heart Failure or Coronary Artery Disease in the US Veterans Affairs System: 2017-2021.
   Am Heart J. 2023 Nov 11:S0002-8703(23)00318-6. doi: 10.1016/j.ahj.2023.
   

   >> Share

   
   September 2023
9. NICHOLLS SJ, Bhatt DL, Buse JB, Prato SD, et al
   Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics.
   Am Heart J. 2023 Sep 25:S0002-8703(23)00280-6. doi: 10.1016/j.ahj.2023.
   

   >> Share

   
   August 2023
10. JAMES S, Erlinge D, Storey RF, McGuire DK, et al
    Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction.
    Am Heart J. 2023 Aug 25:S0002-8703(23)00207-7. doi: 10.1016/j.ahj.2023.
    

    >> Share

    
    
11. HARRINGTON J, Mentz RJ, Rockhold FW, Garg J, et al
    Baseline Characteristics of Patients in the Randomized Study to Investigate the Efficacy and Safety of Ferric Carboxymaltose as Treatment for Heart Failure with Iron Deficiency: HEART-FID Trial.
    Am Heart J. 2023 Aug 18:S0002-8703(23)00202-8. doi: 10.1016/j.ahj.2023.
    

    >> Share

    
    July 2023
12. WILLIAMS BA, Rajpura J, Paprocki YM, Kumar N, et al
    Temporal Trends in Cardiovascular Outcomes and Costs Among Patients with Type 2 Diabetes.
    Am Heart J. 2023 Jul 27:S0002-8703(23)00185-0. doi: 10.1016/j.ahj.2023.
    

    >> Share

    
    May 2023
13. ARNOLD SV, Gosch K, Kosiborod M, Wong ND, et al
    Contemporary Use of Cardiovascular Risk Reduction Strategies in Type 2 Diabetes. Insights from The Diabetes Collaborative Registry.
    Am Heart J. 2023 May 8:S0002-8703(23)00112-6. doi: 10.1016/j.ahj.2023.
    

    >> Share

    
    April 2023
14. DA FONSECA SF, Pinho Ribeiro AL, Rodrigues Cimini CC, de Castro Soares TB, et al
    Scale up of implementation of a multidimensional intervention to enhance hypertension and diabetes care at the primary care setting: a protocol for a cluster-randomized study in Brazil.
    Am Heart J. 2023 Apr 10:S0002-8703(23)00092-3. doi: 10.1016/j.ahj.2023.
    

    >> Share

    
    March 2023
15. GNUDI L, Fountoulakis N, Panagiotou A, Corcillo A, et al
    Effect of active vitamin-D on left ventricular mass index: results of a randomised controlled trial in type 2 diabetes and chronic kidney disease.
    Am Heart J. 2023 Mar 17:S0002-8703(23)00062-5. doi: 10.1016/j.ahj.2023.
    

    >> Share

    
    February 2023
16. KAUL U, Arambam P, Sinha SK, Abhaichand R, et al
    Rationale and design of the TUXEDO-2 India study: Ultra-Thin strUt Supraflex Cruz versus XiencE in a Diabetic pOpulation with multi-vessel disease-2.
    Am Heart J. 2023;256:128-138.
    

    >> Share

    
    December 2022
17. TANG X, Lingzhu Y, Xing Z
    Predicted lean body mass, fat mass, and heart failure in patients with type 2 diabetes mellitus.
    Am Heart J. 2022 Dec 14:S0002-8703(22)00328-3. doi: 10.1016/j.ahj.2022.
    

    >> Share

    
    
18. HORIUCHI Y, Matsue Y, Nogi K, Onitsuka K, et al
    Early treatment with a sodium-glucose co-transporter 2 inhibitor in high-risk patients with acute heart failure: rationale for and design of the EMPA-AHF trial.
    Am Heart J. 2022 Dec 8:S0002-8703(22)00325-8. doi: 10.1016/j.ahj.2022.
    

    >> Share

    
    November 2022
19. JANUZZI JL JR, Butler J, Prato SD, Ezekowitz JA, et al
    Rationale and Design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in Patients with High-Risk Diabetic Cardiomyopathy.
    Am Heart J. 2022 Nov 10. pii: S0002-8703(22)00287.
    

    >> Share

    
    October 2022
20. NELSON AJ, Pagidipati NJ, Kelsey MD, Ardissino M, et al
    COOrdinating CaRDIology CliNics RAndomized Trial of Interventions to Improve OutcomEs (COORDINATE) - Diabetes: Rationale and Design.
    Am Heart J. 2022 Oct 21. pii: S0002-8703(22)00274.
    

    >> Share

    
    
21. LAMAS GA, Anstrom KJ, Navas-Acien A, Boineau R, et al
    The trial to assess chelation therapy 2 (TACT2): Rationale and design.
    Am Heart J. 2022;252:1-11.
    

    >> Share

    
    September 2022
22. DESAI RJ, Glynn RJ, Everett BM, Schneeweiss S, et al
    Comparative effectiveness of empagliflozin in reducing the burden of recurrent cardiovascular hospitalizations among older adults with diabetes in routine clinical care.
    Am Heart J. 2022 Sep 20. pii: S0002-8703(22)00193.
    

    >> Share

    
    July 2022
23. SUZUKI Y, Kaneko H, Yano Y, Okada A, et al
    Glycemic status and the association of change in blood pressure with incident cardiovascular disease.
    Am Heart J. 2022 Jul 21. pii: S0002-8703(22)00148.
    

    >> Share

    
    May 2022
24. HARRINGTON J, Udell JA, Jones WS, Anker SD, et al
    Empagliflozin in Patients Post Myocardial Infarction Rationale and Design of the EMPACT-MI Trial.
    Am Heart J. 2022 May 17. pii: S0002-8703(22)00095.
    

    >> Share

    
    March 2022
25. DUCROCQ G, Bhatt DL, Lee JJ, Kui N, et al
    Balance of Benefit and Risk of Ticagrelor in Patients With Diabetes and Stable Coronary Artery Disease According to Bleeding Risk Assessment With the CRUSADE Score: Data From THEMIS and THEMIS PCI: Abbreviated title: Bleeding risk stratification of ti
    Am Heart J. 2022 Mar 20. pii: S0002-8703(22)00055.
    

    >> Share

    
    
26. GENEREUX P, Chernin G, Assali AR, Peruga JZ, et al
    Double-Blind, Placebo-Controlled Evaluation of Biorest Liposomal Alendronate in Diabetic Patients Undergoing PCI: The BLADE-PCI Trial: The BLADE-PCI Trial.
    Am Heart J. 2022 Mar 16. pii: S0002-8703(22)00052.
    

    >> Share

    
    January 2022
27. PLUTZKY J, Benson MD, Chaney K, Bui TV, et al
    Population health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program.
    Am Heart J. 2022;243:15-27.
    

    >> Share

    
    December 2021
28. RIFAI MA, Mahtta D, Ramsey DJ, Lee MT, et al
    nCorrelates of SGLT-2-inhibitiors Use Among Patients with Atherosclerotic Cardiovascular Disease and Type 2 Diabetes Mellitus: Insights from the Department of Veterans Affairs.
    Am Heart J. 2021 Dec 27. pii: S0002-8703(21)00480.
    

    >> Share

    
    October 2021
29. ARNOLD SV, Khunti K, Tang F, Chen H, et al
    Incidence Rates and Predictors of Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes: Results from the Longitudinal Global DISCOVER Study.
    Am Heart J. 2021 Oct 16. pii: S0002-8703(21)00433.
    

    >> Share

    
    
30. WEAVER AM, McGuinn LA, Neas L, Devlin RB, et al
    Associations between neighborhood socioeconomic cluster and hypertension, diabetes, myocardial infarction, and coronary artery disease within a cohort of cardiac catheterization patients.
    Am Heart J. 2021 Oct 2. pii: S0002-8703(21)00243.
    

    >> Share

    
    
31. SANDHU AT, Kohsaka S, Lin S, Woo CY, et al
    Renin-angiotensin-aldosterone system inhibitors and SARS-CoV-2 infection: an analysis from the veteran's affairs healthcare system.
    Am Heart J. 2021;240:46-57.
    

    >> Share

    
    
32. COTTER G, Davison BA, Edwards C, Senger S, et al
    Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials.
    Am Heart J. 2021;240:73-80.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share